Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFP-derived peptide vaccine vs placebo after TACE in advanced hepatocellular carcinoma
jRCT2041220154Phase 2Recruiting
- Start
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of AFP357 and AFP403 in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Relapse-free survival. Started Mar 2023; status: recruiting.
02
Drugs
AFP357AFP403
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2041220154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220154.